A Phase 4 interventional study of risperidone and aripiprazole in Psychosis; Acute, sponsored by Northwell Health. Recruiting at 1 site in United States. Open to participants aged 15 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-05-26.
Sponsored by Northwell Health · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing risperidone in Psychotic Disorders — 2 open to participants now, 2 under way, 1 of them phase 3. Risperidone · Psychotic Disorders.
Among the 66 studies testing risperidone in Psychotic Disorders, this one is the 24th largest by planned enrollment of the 62 interventional ones that give a count, is one of 2 that started in 2025, is one of 29 in phase 4, and was the 66th registered.
1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.
Browse Psychotic Disorders studies →2 of the 66 studies testing risperidone in Psychotic Disorders are open now, in 1 country. Recruiting first, the newest first:
Louisiana State University Health Sciences Center Shreveport · Sites in United States
Ages 18–65
By country, each count listing its studies:
Risperidone: first FDA approval 1993 (RISPERDAL), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.
This study: 15 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
First in 1996; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 65 across 1,326 interventional studies indexed under Psychotic Disorders.
Median enrollment 98 across the 62 interventional studies. Of the 56 that completed or were terminated, 12 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 66 have an industry lead sponsor. The 10 most frequent:
Northwell Health is the lead sponsor of 476 studies on the registry; 106 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 23 (48%) have results posted.
18 studies in Psychotic Disorders by Northwell Health: 4 open now, 4 under way, none of them phase 3. Of 13 finished, 5 (38%) have results posted.
Among the 18 studies in Psychotic Disorders by Northwell Health, this one is the 6th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2025, is one of 4 in phase 4, and was the 17th registered.
Northwell Health’s Psychotic Disorders studies by the year they started, since 2004.
1 of the studies testing risperidone in Psychotic Disorders that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06482554Phase 3Louisiana State University Health Sciences Center ShreveportLumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 66 studies testing risperidone in Psychotic Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Northwell Health’s 18 in Psychotic Disorders:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study plans to collect 120 patients with first-episode psychosis. Participants will receive multimodal MRI scans (naturalistic fMRI, structural, diffusional) and comprehensive clinical assessments at baseline, and subsequently be treated with either risperidone or aripiprazole for 12 weeks. Clinical assessments for psychotic symptoms will be followed multiple times during the treatment until the 12th week. Data analysis will be conducted at the Psychiatric Research Unit of the Zucker Hillside Hospital.
This study plans to collect 120 patients with first-episode psychosis. Participants will receive multimodal MRI scans (naturalistic fMRI, structural, diffusional) and comprehensive clinical assessments at baseline, and subsequently be treated with either risperidone or aripiprazole for 12 weeks. Clinical assessments for psychotic symptoms will be followed multiple times during the treatment until the 12th week. Data analysis will be conducted at the Psychiatric Research Unit of the Zucker Hillside Hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open label drugs
Drug: risperidone · Drug: aripiprazole
standard treatment, non-randomized
standard treatment, non-randomized
Cerebellar-cortical functional connectivity
To investigate the performance of cerebellar-cortical functional connectivity in prediction of antipsychotic response
Time frame: July 2025 - December 2029
Cerebellar-cortical structural connectivity
To investigate the performance of cerebellar white matter microstructures in prediction of antipsychotic response
Time frame: July 2025 - December 2029
Cerebellar structural-functional integration
To investigate the performance of integrated structural and functional connectivity in prediction of antipsychotic response
Time frame: July 2025 - December 2029
Started Nov 2025 (actual). Primary completion is estimated for Dec 2029, 49 months after the start.
Of 45 non-industry phase 4 interventional studies under Psychotic Disorders, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 71. This study's planned 49 months is below that.
Counting every sponsor, half of 51 studies reached it within 58 months; a quarter within 32 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Risperidone · Aripiprazole